Response assessment of novoTTF-100A versus best physician’s choice chemotherapy in recurrent glioblastoma

Wong, Eric T. ; Swanson, Kenneth D. ; et al.

In: Journal of Clinical Oncology, Jg. 31 (2013-05-20), S. 2080-2080

Online unknown

Zugriff:

2080 Background: The NovoTTF-100A device emits tumor treating electric fields and was tested against Best Physician’s Choice (BPC) chemotherapy in a randomized phase III trial. We analyzed post hoc the characteristics of responders and non-responders in both cohorts. Methods: Macdonald criteria were used to determine tumor response and progression. Kaplan-Meier and Chi-squared statistics were computed for time to response, response duration, progression-free survival (PFS) with and without Simon-Makuch correction, and overall survival (OS). Prognostic factors were compared using the Wilconox rank sum test. Relative hazard rates for responders and non-responders were plotted. Results: The median response duration was 7.3 versus 5.6 months for NovoTTF-100A and BPC chemotherapy respectively (p=0.0009). Five of 14 NovoTTF-100A responders but none of 7 BPC responders had prior low-grade histology. The mean cumulative dexamethasone dose was 35.9 mg for responders versus 485.6 mg for non-responders in the NovoTTF-100A cohort (p2=11.5, P=0.0007) or BPC chemotherapy (χ2=5.2, P=0.0222). The median OS was 24.8 months for responders that is longer than 6.2 months for non-responders treated with NovoTTF-100A (χ2=25.7, P2=5.1, P=0.0235). There was strong Pearson correlation between response and OS in NovoTTF-100A (P

Titel:	Response assessment of novoTTF-100A versus best physician’s choice chemotherapy in recurrent glioblastoma
Autor/in / Beteiligte Person:	Wong, Eric T. ; Swanson, Kenneth D. ; Gautam, Shiva ; Lok, Edwin ; Villano, John L. ; Engelhard, Herbert H. ; Taillibert, Sophie ; Lieberman, Frank S. ; Ram, Zvi ; Beth Israel Deaconess Medical Center ; Harvard Medical School [Boston] (HMS) ; University of Illinois [Chicago] (UIC) ; University of Illinois System ; University of Pittsburgh School of Medicine ; Pennsylvania Commonwealth System of Higher Education (PCSHE) ; UPMC - Département de neurologie 2 - Mazarin ; Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP] ; Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) ; Tel Aviv Sourasky Medical Center [Te Aviv] ; University of Kentucky
Link:	View record in OpenAIRE (Volltext) https://doi.org/10.1200/jco.2013.31.15_suppl.2080
Zeitschrift:	Journal of Clinical Oncology, Jg. 31 (2013-05-20), S. 2080-2080
Veröffentlichung:	American Society of Clinical Oncology (ASCO), 2013
Medientyp:	unknown
ISSN:	1527-7755 (print) ; 0732-183X (print) ; 2045-7634 (print)
DOI:	10.1200/jco.2013.31.15_suppl.2080
Schlagwort:	Adult Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Mitosis [SDV.CAN]Life Sciences [q-bio]/Cancer NovoTTF-100A Tumor response Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology, Nuclear Medicine and imaging Dexamethasone Aged Original Research Chemotherapy response Brain Neoplasms business.industry Electromagnetic Radiation Recurrent glioblastoma Histology Middle Aged Surgery 3. Good health Response assessment Clinical Trials, Phase III as Topic Equipment and Supplies Tumor progression Relative hazard 030220 oncology & carcinogenesis Toxicity Cohort Dexamethasone Dose Neoplasm Recurrence, Local Response Duration Glioblastoma business medicine.drug recurrent glioblastoma 030215 immunology
Sonstiges:	Nachgewiesen in: OpenAIRE Rights: OPEN

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.